Bilaketaren emaitzak - Somnath Sarkar
- Erakusten 1 - 8 emaitzak -- 8
-
1
Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials nork Fairooz F. Kabbinavar, Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, Oliver Rosen
Argitaratua 2008Artigo -
2
-
3
-
4
-
5
-
6
Contribution of Raloxifene and Calcium and Vitamin D<sub>3</sub>Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women nork G. Boivin, Paul Lips, Susan M. Ott, Kristine D. Harper, Somnath Sarkar, Karen V. Pinette, Pierre J. Meunier
Argitaratua 2003Artigo -
7
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107 nork Axel Grothey, Eric Hedrick, R. Mass, Somnath Sarkar, Sam Suzuki, Ramesh K. Ramanathan, Herbert I. Hurwitz, Richard M. Goldberg, Daniel J. Sargent
Argitaratua 2008Artigo -
8
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial nork Pierre D. Delmas, Kristine E. Ensrud, Jonathan D. Adachi, Kristine D. Harper, Somnath Sarkar, C. Gennari, Jean‐Yves Reginster, Huibert A. P. Pols, Robert R. Recker, Steven T. Harris, Wentao Wu, Harry K. Genant, Dennis M. Black, Richard Eastell
Argitaratua 2002Artigo
Bilaketa egiteko lanabesak:
Antzeko gaiak
Cancer
Internal medicine
Medicine
Surgery
Breast cancer
Osteoporosis
Raloxifene
Alternative medicine
Confidence interval
Estrogen receptor
Pathology
Placebo
Bevacizumab
Bone mineral
Chemotherapy
Colorectal cancer
Fluorouracil
Hazard ratio
Oncology
Urology
Cohort
Femoral neck
Irinotecan
Progression-free survival
Randomized controlled trial
Adverse effect
Bone density
Bone remodeling
Cumulative incidence
Dentistry